{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:31:10Z","timestamp":1794137470237,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Most of the clinical and economic burden of Respiratory Syncytial Virus (RSV) in pediatric populations is concentrated among infants aged\u2009&lt;\u20091 year. This study aimed to estimate the recent incidence, healthcare costs and rehospitalization risk associated with RSV-related hospitalizations in infants\u2009&lt;\u20091 year of age in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study analyzed the French National Hospital Database (PMSI) between January 1, 2016 and December 31, 2023. Outside of the classically defined epidemic season (October\u2013March), RSV-related hospitalizations in infants were identified based on RSV-specific diagnosis codes and by both specific and non-specific RSV diagnosis codes during the epidemic season. Analyses were stratified by calendar months, by age in months and weeks for infants under 2 months. Lengths of stays (LOS), intensive care units (ICU) admissions, costs and rehospitalization rates were described. Rehospitalization rate was assessed using the Kaplan-Meier estimator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 354,837 RSV-related hospitalizations were identified, representing an average of 44,355 per year, and a rate of 4.9 hospitalizations per 1,000 births. Overall, 76.4% occurred between November and February (epidemic peak), and 21.1% in September-October and March-April (transition months). ICU admission was observed in 27.2% of hospitalizations. The median (Q1\u2013Q3) hospital and ICU LOS were 3.0 days (1.0\u20135.0) and 3.0 days (2.0\u20135.0), respectively. The mean (SD) hospital cost was \u20ac3,110 (\u20ac4,694), for an annual cumulative cost of \u20ac137.9\u00a0million. Younger infants had longer and costlier stays, with greater need for ICU. Infants younger than 3 months accounted for 46.5% of the hospitalizations, 58.5% of ICU stays and 54.9% of cumulative LOS. RSV-associated rehospitalization rates [95%CI] were 10.1% [10.0%\u201310.3%] and 11.7% [11.5%\u201311.9%] at three and 12 months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RSV infections are estimated to cause\u2009&gt;\u200944,000 hospitalizations annually in infants in France, representing a total cost exceeding \u20ac130\u00a0million, annually. This study highlighted the impact of transitional months in RSV circulation. It also emphasized that the youngest patients (&lt;\u20093 months) represent nearly 50% of the economic burden. To reduce RSV disease burden, it is essential to protect infants against RSV both inside and outside the classically defined epidemic season, especially in the first months of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12039-2","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:19:51Z","timestamp":1763630391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epidemiology and economic burden of hospitalizations attributable to Respiratory Syncytial Virus (RSV) infection among infants in France, 2016 to 2023 \u2013 EPIBREATHE study"],"prefix":"10.1186","volume":"25","author":[{"given":"Robert","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta C.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Chillotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Kernaleguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bugnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Fahfouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Fi\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Charkaluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"12039_CR1","first-page":"94","volume":"95","author":"DK Smith","year":"2017","unstructured":"Smith DK, Seales S, Budzik C. Respiratory syncytial virus bronchiolitis in children. Am Fam Physician. 2017;95:94\u20139.","journal-title":"Am Fam Physician"},{"key":"12039_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1413456","volume":"374","author":"HC Meissner","year":"2016","unstructured":"Meissner HC. Viral bronchiolitis in children. N Engl J Med. 2016;374:62\u201372. https:\/\/doi.org\/10.1056\/NEJMra1413456.","journal-title":"N Engl J Med"},{"key":"12039_CR3","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1093\/cid\/cix148","volume":"64","author":"DR Feikin","year":"2017","unstructured":"Feikin DR, Fu W, Park DE, Shi Q, Higdon MM, Baggett HC, et al. Is higher viral load in the upper respiratory tract associated with severe pneumonia? Findings from the PERCH study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;64:S337\u201346. https:\/\/doi.org\/10.1093\/cid\/cix148.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"12039_CR4","doi-asserted-by":"publisher","first-page":"e15352","DOI":"10.15252\/emmm.202115352","volume":"14","author":"G Neumann","year":"2022","unstructured":"Neumann G, Kawaoka Y. Seasonality of influenza and other respiratory viruses. EMBO Mol Med. 2022;14:e15352. https:\/\/doi.org\/10.15252\/emmm.202115352.","journal-title":"EMBO Mol Med"},{"key":"12039_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/infdis\/jiy056","volume":"217","author":"P Obando-Pacheco","year":"2018","unstructured":"Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodr\u00edguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory syncytial virus seasonality: A global overview. J Infect Dis. 2018;217:1356\u201364. https:\/\/doi.org\/10.1093\/infdis\/jiy056.","journal-title":"J Infect Dis"},{"key":"12039_CR6","volume-title":"Bronchiolitis. StatPearls","author":"NA Justice","year":"2023","unstructured":"Justice NA, Le JK. Bronchiolitis. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"12039_CR7","doi-asserted-by":"publisher","first-page":"CD013757","DOI":"10.1002\/14651858.CD013757.pub2","volume":"11","author":"L Garegnani","year":"2021","unstructured":"Garegnani L, Styrmisd\u00f3ttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11:CD013757. https:\/\/doi.org\/10.1002\/14651858.CD013757.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"12039_CR8","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. SYNAGIS (palivizumab). Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/c_2756580\/fr\/synagis-palivizumab (accessed February 13, 2023)."},{"key":"12039_CR9","unstructured":"European Medicines Agency. BEYFORTUS (nirsevimab). Eur Med Agency 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus (accessed July 13, 2023)."},{"key":"12039_CR10","unstructured":"Direction G\u00e9n\u00e9rale de la Sant\u00e9. DGS-URGENT - Nirsevimab n.d."},{"key":"12039_CR11","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Abrysvo - Comission de la Transparence n.d. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-20783_ABRYSVO_femmes_enceintes_PIC_INS_AvisDef_CT20783.pdf"},{"key":"12039_CR12","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12879-021-06399-8","volume":"21","author":"C Demont","year":"2021","unstructured":"Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, et al. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21:730. https:\/\/doi.org\/10.1186\/s12879-021-06399-8.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 4","key":"12039_CR13","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a National administrative database to guide public decisions: from the syst\u00e8me National d\u2019information interr\u00e9gimes de l\u2019assurance maladie (SNIIRAM) to the syst\u00e8me National des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149\u201367. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"12039_CR14","doi-asserted-by":"publisher","unstructured":"Beese C, Bayer L, Huebbe B, Riedel J, Melnik S, Brestrich G et al. Clinical and economic burden of lower respiratory tract infection due to respiratory syncytial virus in young children in Germany 2024:2024.02.12.24302675. https:\/\/doi.org\/10.1101\/2024.02.12.24302675","DOI":"10.1101\/2024.02.12.24302675"},{"key":"12039_CR15","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1093\/infdis\/jiac185","volume":"226","author":"JR Gantenberg","year":"2022","unstructured":"Gantenberg JR, van Aalst R, Zimmerman N, Limone B, Chaves SS, La Via WV, et al. Medically attended illness due to respiratory syncytial virus infection among infants born in the united States between 2016 and 2020. J Infect Dis. 2022;226:S164\u201374. https:\/\/doi.org\/10.1093\/infdis\/jiac185.","journal-title":"J Infect Dis"},{"key":"12039_CR16","unstructured":"Institut National de la Statistique et des Etudes Economiques. Donn\u00e9es nationales sur les accouchements\u2009\u2013\u2009Les naissances en 2023 et en s\u00e9ries longues | Insee n.d. https:\/\/www.insee.fr\/fr\/statistiques\/8256967?sommaire=8256973 (accessed March 26, 2025)."},{"key":"12039_CR17","unstructured":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation. Etude Nationale des Co\u00fbts MCO n.d. https:\/\/www.scansante.fr\/applications\/enc-mco (accessed September 12, 2025)."},{"key":"12039_CR18","unstructured":"Institut national de la statistique et des \u00e9tudes \u00e9conomiques. Taux d\u2019inflation | Insee n.d. https:\/\/www.insee.fr\/fr\/statistiques\/2122401 (accessed September 27, 2023)."},{"key":"12039_CR19","unstructured":"D\u00e9lib\u00e9ration n\u00b0. 2018\u2009\u2013\u2009257 du 7 juin 2018 portant homologation d\u2019une m\u00e9thodologie de r\u00e9f\u00e9rence relative aux traitements de donn\u00e9es n\u00e9cessitant l\u2019acc\u00e8s pour le compte des personnes produisant ou commercialisant des produits mentionn\u00e9s au II de l\u2019article L. 5311-1 du code de la sant\u00e9 publique aux donn\u00e9es du PMSI centralis\u00e9es et mises \u00e0 disposition par l\u2019ATIH par l\u2019interm\u00e9diaire d\u2019une solution s\u00e9curis\u00e9e (MR 006) - L\u00e9gifrance. 2018."},{"key":"12039_CR20","unstructured":"Commission nationale de l\u2019informatique et des libert\u00e9s. \u00c9tudes n\u00e9cessitant l\u2019acc\u00e8s aux donn\u00e9es du PMSI par les industriels de sant\u00e9 n.d. https:\/\/www.cnil.fr\/fr\/declaration\/mr-006-etudes-necessitant-lacces-aux-donnees-du-pmsi-par-les-industriels-de-sante (accessed September 27, 2023)."},{"key":"12039_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12879-023-08358-x","volume":"23","author":"F Martin\u00f3n-Torres","year":"2023","unstructured":"Martin\u00f3n-Torres F, Carmo M, Platero L, Drago G, L\u00f3pez-Belmonte JL, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015\u20132018. BMC Infect Dis. 2023;23:385. https:\/\/doi.org\/10.1186\/s12879-023-08358-x.","journal-title":"BMC Infect Dis"},{"key":"12039_CR22","doi-asserted-by":"publisher","first-page":"e13066","DOI":"10.1111\/irv.13066","volume":"17","author":"T Bandeira","year":"2023","unstructured":"Bandeira T, Carmo M, Lopes H, Gomes C, Martins M, Guzman C, et al. Burden and severity of children\u2019s hospitalizations by respiratory syncytial virus in Portugal, 2015\u20132018. Influenza Other Respir Viruses. 2023;17:e13066. https:\/\/doi.org\/10.1111\/irv.13066.","journal-title":"Influenza Other Respir Viruses"},{"key":"12039_CR23","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recommandation vaccinale contre les infections \u00e0 VRS chez les femmes enceintes. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/p_3505344\/fr\/recommandation-vaccinale-contre-les-infections-a-vrs-chez-les-femmes-enceintes (accessed April 23, 2025)."},{"key":"12039_CR24","doi-asserted-by":"publisher","first-page":"2100619","DOI":"10.2807\/1560-7917.ES.2022.27.16.2100619","volume":"27","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Broberg EK, Campbell H, Nair H, Redlberger-Fritz M, et al. Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019. Eurosurveillance. 2022;27:2100619. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.16.2100619.","journal-title":"Eurosurveillance"},{"key":"12039_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","volume":"72","author":"S Hamid","year":"2023","unstructured":"Hamid S, Winn A, Parikh R, Jones JM, McMorrow M, Prill MM, et al. Seasonality of respiratory syncytial Virus - United States, 2017\u20132023. MMWR Morb Mortal Wkly Rep. 2023;72:355\u201361. https:\/\/doi.org\/10.15585\/mmwr.mm7214a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"12039_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1055\/s-0036-1584147","volume":"34","author":"EJ Anderson","year":"2017","unstructured":"Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Sim\u00f5es EAF, et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. Infants born at 29 to 35 weeks\u2019 gestational age not receiving immunoprophylaxis. Am J Perinatol. 2017;34:51\u201361. https:\/\/doi.org\/10.1055\/s-0036-1584147.","journal-title":"Am J Perinatol"},{"key":"12039_CR27","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","volume":"226","author":"M Suh","year":"2022","unstructured":"Suh M, Movva N, Jiang X, Bylsma LC, Reichert H, Fryzek JP, et al. Respiratory syncytial virus is the leading cause of united States infant Hospitalizations, 2009\u20132019: A study of the National (Nationwide) inpatient sample. J Infect Dis. 2022;226:S154\u201363. https:\/\/doi.org\/10.1093\/infdis\/jiac120.","journal-title":"J Infect Dis"},{"key":"12039_CR28","unstructured":"CDC, Respir Syncytial Virus Infect RSV-NET. RSV 2025. https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/rsv-net.html (accessed May 6, 2025)."},{"key":"12039_CR29","doi-asserted-by":"publisher","first-page":"e11491","DOI":"10.1097\/MD.0000000000011491","volume":"97","author":"R Sruamsiri","year":"2018","unstructured":"Sruamsiri R, Kubo H, Mahlich J. Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus. Med (Baltim). 2018;97:e11491. https:\/\/doi.org\/10.1097\/MD.0000000000011491.","journal-title":"Med (Baltim)"},{"key":"12039_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1086\/599347","volume":"49","author":"RM de Voer","year":"2009","unstructured":"de Voer RM, van der Klis FRM, Nooitgedagt JE, Versteegh FGA, van Huisseling JCM, van Rooijen DM, et al. Seroprevalence and placental transportation of maternal antibodies specific for neisseria meningitidis serogroup C, haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49:58\u201364. https:\/\/doi.org\/10.1086\/599347.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"12039_CR31","doi-asserted-by":"crossref","unstructured":"Albrecht M, Arck PC. Vertically transferred immunity in neonates: Mothers, mechanisms and mediators. Front Immunol 2020;11.","DOI":"10.3389\/fimmu.2020.00555"},{"key":"12039_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3389\/fimmu.2014.00446","volume":"5","author":"S Niewiesk","year":"2014","unstructured":"Niewiesk S. Maternal antibodies: clinical Significance, mechanism of interference with immune Responses, and possible vaccination strategies. Front Immunol. 2014;5:446. https:\/\/doi.org\/10.3389\/fimmu.2014.00446.","journal-title":"Front Immunol"},{"key":"12039_CR33","doi-asserted-by":"publisher","unstructured":"Sarna M, Le H, Taye BW, Glass K, Levy A, Richmond P, et al. Clinical outcomes and severity of laboratory-confirmed RSV compared with influenza, parainfluenza and human metapneumovirus in Australian children attending secondary care. BMJ Open Respir Res. 2024;11. https:\/\/doi.org\/10.1136\/bmjresp-2024-002613.","DOI":"10.1136\/bmjresp-2024-002613"},{"key":"12039_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/children12020183","volume":"12","author":"R Lee","year":"2025","unstructured":"Lee R, Ding T, Riddell CA, Hartert T, Wu P. Incidence of and risk factors for subsequent lower respiratory tract infection following an infant RSV hospitalization. Children. 2025;12:183. https:\/\/doi.org\/10.3390\/children12020183.","journal-title":"Children"},{"key":"12039_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1186\/s12913-023-09631-0","volume":"23","author":"Z Ebrahimi Rigi","year":"2023","unstructured":"Ebrahimi Rigi Z, Namjoo Z, Jabarpour M, Ahmadinejad M, Ahmadipour M, Mangolian Shahrbabaki P, et al. Hospital challenges and managerial approaches to combat COVID-19 outbreak: a qualitative study in southeastern Iran. BMC Health Serv Res. 2023;23:690. https:\/\/doi.org\/10.1186\/s12913-023-09631-0.","journal-title":"BMC Health Serv Res"},{"key":"12039_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/covid5060077","volume":"5","author":"G Abdolahzadeh","year":"2025","unstructured":"Abdolahzadeh G, Stentz TL, Lather JI, Kim K, Willet K. A phenomenological study on the challenges faced by Nebraska hospitals during the COVID-19 outbreak. COVID. 2025;5:77. https:\/\/doi.org\/10.3390\/covid5060077.","journal-title":"COVID"},{"key":"12039_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/v15010041","volume":"15","author":"E Amodio","year":"2022","unstructured":"Amodio E, De Grazia S, Genovese D, Bonura F, Filizzolo C, Collura A, et al. Clinical and epidemiologic features of viral gastroenteritis in hospitalized children: an 11-Year surveillance in Palermo (Sicily). Viruses. 2022;15:41. https:\/\/doi.org\/10.3390\/v15010041.","journal-title":"Viruses"},{"key":"12039_CR38","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.siny.2019.101073","volume":"25","author":"TM Raffay","year":"2020","unstructured":"Raffay TM, Martin RJ. Intermittent hypoxia and bronchial hyperreactivity. Semin Fetal Neonatal Med. 2020;25:101073. https:\/\/doi.org\/10.1016\/j.siny.2019.101073.","journal-title":"Semin Fetal Neonatal Med"},{"key":"12039_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.arbres.2024.02.009","volume":"60","author":"H Makrinioti","year":"2024","unstructured":"Makrinioti H, Zhu Z, Saglani S, Camargo CA, Hasegawa K. Infant bronchiolitis endotypes and the risk of developing childhood asthma: lessons from cohort studies. Arch Bronconeumol. 2024;60:215\u201325. https:\/\/doi.org\/10.1016\/j.arbres.2024.02.009.","journal-title":"Arch Bronconeumol"},{"key":"12039_CR40","unstructured":"Sant\u00e9 Publique France. Bronchiolite: bilan de la surveillance hivernale 2022\u20132023 | Sant\u00e9 publique France n.d. https:\/\/www.santepubliquefrance.fr\/les-actualites\/2023\/bronchiolite-bilan-de-la-surveillance-hivernale-2022-2023 (accessed April 25, 2025)."},{"key":"12039_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/INF.0000000000004360","volume":"43","author":"A Rybak","year":"2024","unstructured":"Rybak A, Cohen R, Bangert M, Kramer R, Delobbe J-F, Deberdt P, et al. Assessing the burden of respiratory syncytial Virus-related bronchiolitis in primary care and at 15-Day and 6-Month Follow-up before prophylaxis in france: A Test-negative study. Pediatr Infect Dis J. 2024;43:657\u201362. https:\/\/doi.org\/10.1097\/INF.0000000000004360.","journal-title":"Pediatr Infect Dis J"},{"key":"12039_CR42","first-page":"297","volume":"54","author":"M Goldberg","year":"2006","unstructured":"Goldberg M. Les bases de donn\u00e9es d\u2019origine administrative peuvent-elles \u00eatre utiles pour l\u2019\u00e9pid\u00e9miologie ? Revue d\u2019\u00c9pid\u00e9miologie. Et De Sant\u00e9 Publique. 2006;54:297\u2013303.","journal-title":"Et De Sant\u00e9 Publique"},{"key":"12039_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0398-7620(04)99032-3","volume":"52","author":"P Fender","year":"2004","unstructured":"Fender P, Weill A. \u00c9pid\u00e9miologie, sant\u00e9 publique et bases de donn\u00e9es m\u00e9dico-tarifaires. Revue d\u2019\u00c9pid\u00e9miologie Et De Sant\u00e9 Publique. 2004;52:113\u20137.","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie Et De Sant\u00e9 Publique"},{"key":"12039_CR44","unstructured":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation. Statistiques ATIH - MCO par diagnostic ou acte n.d. https:\/\/www.scansante.fr\/applications\/statistiques-activite-MCO-par-diagnostique-et-actes\/submit?snatnav=&annee=2019&type_cat_etab=deux&type_code=cim&code=J219&niveau=0&codh=0000000000 (accessed February 13, 2023)."},{"key":"12039_CR45","doi-asserted-by":"publisher","first-page":"e0319436","DOI":"10.1371\/journal.pone.0319436","volume":"20","author":"AL Bierrenbach","year":"2025","unstructured":"Bierrenbach AL, Ranzani OT. Evaluating the accuracy of ICD-10 codes for syncytial respiratory virus diagnosis in hospitalized patients: A record-linkage study (2022\u20132023). PLoS ONE. 2025;20:e0319436. https:\/\/doi.org\/10.1371\/journal.pone.0319436.","journal-title":"PLoS ONE"},{"key":"12039_CR46","doi-asserted-by":"publisher","first-page":"2400748","DOI":"10.2807\/1560-7917.ES.2025.30.27.2400748","volume":"30","author":"MA Sanchez Ruiz","year":"2025","unstructured":"Sanchez Ruiz MA, Marques DF, Lomholt FK, Vestergaard LS, Monge S, Lozano \u00c1lvarez M, et al. Surveillance of severe acute respiratory infections associated with SARS-CoV-2, influenza virus and RSV using ICD-10 codes: a case definition accuracy study across five European countries, 2021 to 2023. Eurosurveillance. 2025;30:2400748. https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.27.2400748.","journal-title":"Eurosurveillance"},{"key":"12039_CR47","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/irv.12665","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14:630\u20137. https:\/\/doi.org\/10.1111\/irv.12665.","journal-title":"Influenza Other Respir Viruses"},{"key":"12039_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/14737159.2025.2527635","volume":"25","author":"J Dessajan","year":"2025","unstructured":"Dessajan J, Berti V, Armand-Lef\u00e8vre L, Voiriot G, Fartoukh M, Timsit J-F. Can multiplex molecular panels of microbial pathogens transform respiratory care in critically ill patients? Expert Rev Mol Diagn. 2025;25:525\u201343. https:\/\/doi.org\/10.1080\/14737159.2025.2527635.","journal-title":"Expert Rev Mol Diagn"},{"key":"12039_CR49","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3390\/diagnostics15172249","volume":"15","author":"R-S Mboumba Bouassa","year":"2025","unstructured":"Mboumba Bouassa R-S, Lukumbisa S, B\u00e9lec L. Simultaneous detection and differentiation of SARS-CoV-2, influenza A\/B, and respiratory syncytial viruses in respiratory specimens using the VitaSIRO solo\u2122 SARS-CoV-2\/Flu\/RSV assay. Diagn Basel Switz. 2025;15:2249. https:\/\/doi.org\/10.3390\/diagnostics15172249.","journal-title":"Diagn Basel Switz"},{"key":"12039_CR50","unstructured":"Sant\u00e9 Publique France. Infections respiratoires aigu\u00ebs (grippe, bronchiolite, COVID-19). Bilan de la saison 2024\u20132025. Httpswwwsantepubliquefrancefrmaladies\u2013Traumatismesmaladies\u2013Infect-Respir-Natl-Respir-Aigues-Grippe-Bronchiolite-Covid-19\u2013Bilan\u2014Saison-2024-2025 n.d."},{"key":"12039_CR51","doi-asserted-by":"publisher","first-page":"e2021052089","DOI":"10.1542\/peds.2021-052089","volume":"148","author":"R Agha","year":"2021","unstructured":"Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics. 2021;148:e2021052089. https:\/\/doi.org\/10.1542\/peds.2021-052089.","journal-title":"Pediatrics"},{"key":"12039_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00430-021-00720-7","volume":"210","author":"P Stamm","year":"2021","unstructured":"Stamm P, Sagoschen I, Weise K, Plachter B, M\u00fcnzel T, Gori T, et al. Influenza and RSV incidence during COVID-19 pandemic-an observational study from in-hospital point-of-care testing. Med Microbiol Immunol (Berl). 2021;210:277\u201382. https:\/\/doi.org\/10.1007\/s00430-021-00720-7.","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"12039_CR53","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1002\/ppul.25582","volume":"56","author":"G Di Mattia","year":"2021","unstructured":"Di Mattia G, Nenna R, Mancino E, Rizzo V, Pierangeli A, Villani A, et al. During the COVID-19 pandemic where has respiratory syncytial virus gone? Pediatr Pulmonol. 2021;56:3106\u20139. https:\/\/doi.org\/10.1002\/ppul.25582.","journal-title":"Pediatr Pulmonol"},{"key":"12039_CR54","doi-asserted-by":"publisher","unstructured":"Saravanos GL, Hu N, Homaira N, Muscatello DJ, Jaffe A, Bartlett AW et al. RSV epidemiology in Australia before and during COVID-19. Pediatrics 2022;149:e2021053537. https:\/\/doi.org\/10.1542\/peds.2021-053537","DOI":"10.1542\/peds.2021-053537"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12039-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:14:38Z","timestamp":1781615678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12039"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12039-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study which required processing of personal data for the purpose of research in the field of health falls under the French Data Protection Act, as described in The French Data Protection Agency (Commission Nationale de l\u2019Informatique et des Libert\u00e9s \u2013 CNIL) opinion n\u00b02018\u2009\u2212\u2009257 of 7 June 2018 on regulatory requirements and governance for processing PMSI data under expedited regulatory process (MR-006). This study was conducted in full compliance with relevant guidelines \u2013 including the Declaration of Helsinki, as well as the ICMJE guidelines \u2013 and French regulations. This study was conducted using anonymized data extracted from an existing database (PMSI); thus, according to French regulations and MR-006 process, there is no need for an informed consent from patients nor for an approval of an Ethic committee or an Institutional Review Board. Patients retain the right to withdraw or object by submitting an explicit request to their local insurance branch (CPAM), in accordance with article 111 of the application decree n\u00b0 2019\u2009\u2212\u2009536 of 29 May 2019, under the Data Protection Act. Detailed instructions for this process are available at: https:\/\/www.health-data-hub.fr\/politique-de-confidentialite. A collective information note has been added to both st\u00e8ve consultants and Pfizer websites for this purpose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No informed consent was required as per Decree no. 2021\u2009\u2212\u2009848 of June 29, 2021, of French Public Health Code.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RC: Consulting fees from Pfizer, Sanofi, MSD, GSK, Viatris, Cerballiance. Payment for honoraria from Pfizer, MSD, GSK, Sanofi. Payment for expert testimony from Pfizer, MSD. Travel grants from Pfizer, MSD, Sanofi, GSK. Participation to Data Safety Monitoring Board or Advisory Board for Pfizer, Sanofi, MSD, GSK MN: Consulting fees from Pfizer, research funding from Sanofi. AR: personal fees from Pfizer and from MSD outside the submitted work and nonfinancial support from Pfizer and AstraZeneca. LC, CK, FB: employees of st\u00e8ve consultants, under research contract with Pfizer WG, YF, SF, EB: employees of Pfizer. CL: grants to the institution ACTIV from GSK, Sanofi, Pfizer, and Merck and personal fees and non-financial support from Pfizer and Merck outside the conduct of the study. MLC: Consulting and presentation fees from Pfizer, presentation fees and advisory board participation for Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1621"}}